Sunday 11 October 2026
Export all SNY data to Excel Powerpack
Sanofi
SNY Healthcare Drug Manufacturers General
Sanofi’s revenue for fiscal 2025 (year ended December 2025) was $52.9 billion, up 10.3% from fiscal 2024. In the quarter to June 2026, revenue grew 17.4%, EPS fell 90.8%, free cash flow fell 45.1% and total debt rose 8.23%, each against the same quarter a year earlier. Dividend growth for three consecutive years.
40.07
0.16
−0.40%
Follow SNY
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
22.34 | 13.46 | 13.46 | 11.29 |
+8 more quarters Free account |
P/S ratio |
1.79 | 2.12 | 2.24 | 2.46 | |
P/FCF ratio |
7.02 | 6.24 | 6.36 | 13.00 | |
P/Operating CF |
18.91 | 9.54 | 9.73 | 62.81 | |
P/B ratio |
1.26 | 1.43 | 1.46 | 1.44 | |
Price to Tangible BV |
70.02 | 422.81 | 25.20 | 0.00 | |
EV/Sales |
2.11 | 2.39 | 2.47 | 2.73 | |
EV/EBITDA |
11.54 | 13.31 | 13.29 | 13.10 | |
EV/Operating CF |
5.55 | 5.03 | 5.02 | 8.30 | |
EV/FCF |
8.25 | 7.03 | 7.02 | 14.45 | |
Quick Ratio |
0.49 | 0.20 | 0.58 | 0.29 | |
Current Ratio |
0.99 | 1.01 | 1.09 | 1.06 | |
Net Debt/EBITDA |
7.13 | 6.08 | 10.99 | 2.97 | |
Debt/Assets |
16.79% | 14.23% | 14.66% | 15.33% | |
Debt/Equity |
0.31 | 0.25 | 0.26 | 0.27 | |
Asset Turnover |
0.39 | 0.38 | 0.37 | 0.32 | |
Operating CF/Net income |
13.54 | 0.00 | (13.83) | 0.00 | |
Capex/Depreciation |
(0.30) | — | (0.47) | — | |
Interest Coverage |
7.49 | 11.72 | (54.17) | 16.29 | |
Research and Development Expense of Revenue |
18.15% | 15.54% | 18.84% | 13.93% | |
Selling, General and Administrative Expense of Revenue |
20.04% | 20.70% | 22.59% | 17.40% | |
Intangible Assets out of Total Assets |
0.53 | 0.54 | 0.53 | 0.53 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Graham Net Nets |
(0.32) | (0.25) | (0.23) | (0.23) | |
Graham Number |
38.11 | 0.00 | 51.89 | 0.00 | |
Earnings Yield |
4.48% | 7.43% | 7.43% | 8.86% | |
Free Cash Flow Yield |
14.24% | 16.04% | 15.73% | 7.69% | |
Revenue per Share |
5.98 | 5.46 | 5.78 | 6.32 | |
Operating CF per Share |
2.26 | 0.00 | 4.98 | 0.00 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
2.26 | 0.00 | 4.98 | 0.00 | |
Cash per Share |
3.09 | 2.69 | 3.55 | 4.27 | |
Shareholders Equity per Share |
33.80 | 35.55 | 33.24 | 35.28 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
33.80 | 35.55 | 33.24 | 35.28 | |
Free Cash Flow |
5,398.42 | — | 12,162.55 | — | |
Working Capital |
(474.38) | 182.59 | 2,949.56 | 2,264.16 | |
Capital Expenditures |
(1,013.87) | — | (3,044.60) | — | |
Net Current Asset Value |
(32,521.88) | (28,928.77) | (27,315.39) | (25,971.78) | |
EV/EBIT |
11.54 | 13.31 | 13.29 | 13.10 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
9.83 | 11.81 | 12.03 | 11.78 | |
| Other line items | |||||
Average Receivables |
10,010.20 | 517.52 | 9,527.48 | 5,031.52 | |
Average Payables |
8,172.42 | 24,674.95 | 8,249.59 | 16,860.20 | |
Average Inventory |
11,927.86 | 25,263.44 | 10,880.71 | 20,032.03 | |
Average Assets |
145,955.80 | 144,393.75 | 143,583.95 | 145,724.70 | |
Average Common Equity |
79,748.01 | — | 80,802.47 | — |
Columns are period end dates